nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—CYP3A4—Pilocarpine—glaucoma	0.101	0.166	CbGbCtD
Linagliptin—ABCB1—Timolol—glaucoma	0.0968	0.159	CbGbCtD
Linagliptin—ABCB1—Clonidine—glaucoma	0.0823	0.135	CbGbCtD
Linagliptin—CYP3A4—Brinzolamide—glaucoma	0.0792	0.13	CbGbCtD
Linagliptin—CYP3A4—Dorzolamide—glaucoma	0.0765	0.126	CbGbCtD
Linagliptin—CYP3A4—Methazolamide—glaucoma	0.0682	0.112	CbGbCtD
Linagliptin—CYP3A4—Acetazolamide—glaucoma	0.0545	0.0897	CbGbCtD
Linagliptin—CYP3A4—Clonidine—glaucoma	0.0493	0.0811	CbGbCtD
Linagliptin—Diabetic—Carteolol—glaucoma	0.0183	0.0481	CcSEcCtD
Linagliptin—Diabetic—Levobunolol—glaucoma	0.0173	0.0454	CcSEcCtD
Linagliptin—Bronchial hyperreactivity—Brinzolamide—glaucoma	0.0132	0.0347	CcSEcCtD
Linagliptin—Bronchial hyperreactivity—Timolol—glaucoma	0.00723	0.019	CcSEcCtD
Linagliptin—Diabetes mellitus—Carteolol—glaucoma	0.00511	0.0134	CcSEcCtD
Linagliptin—Diabetes mellitus—Levobunolol—glaucoma	0.00482	0.0127	CcSEcCtD
Linagliptin—Hypoglycaemia—Carteolol—glaucoma	0.00455	0.0119	CcSEcCtD
Linagliptin—Hypoglycaemia—Levobunolol—glaucoma	0.0043	0.0113	CcSEcCtD
Linagliptin—Hyperlipidaemia—Betaxolol—glaucoma	0.0032	0.0084	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Latanoprost—glaucoma	0.00313	0.0082	CcSEcCtD
Linagliptin—Hypersensitivity—Dipivefrin—glaucoma	0.00309	0.0081	CcSEcCtD
Linagliptin—Diabetes mellitus—Brimonidine—glaucoma	0.00307	0.00805	CcSEcCtD
Linagliptin—Urinary tract infection—Latanoprost—glaucoma	0.00291	0.00765	CcSEcCtD
Linagliptin—Hypoglycaemia—Acetazolamide—glaucoma	0.00285	0.00748	CcSEcCtD
Linagliptin—Nasopharyngitis—Apraclonidine—glaucoma	0.00278	0.0073	CcSEcCtD
Linagliptin—Nasopharyngitis—Bimatoprost—glaucoma	0.0027	0.00708	CcSEcCtD
Linagliptin—Hypoglycaemia—Dorzolamide—glaucoma	0.00261	0.00686	CcSEcCtD
Linagliptin—Pain in extremity—Dorzolamide—glaucoma	0.00255	0.00669	CcSEcCtD
Linagliptin—Cough—Metipranolol—glaucoma	0.00252	0.00661	CcSEcCtD
Linagliptin—Pain in extremity—Brinzolamide—glaucoma	0.00251	0.00658	CcSEcCtD
Linagliptin—Hypoglycaemia—Pilocarpine—glaucoma	0.00247	0.00648	CcSEcCtD
Linagliptin—Myalgia—Metipranolol—glaucoma	0.00246	0.00645	CcSEcCtD
Linagliptin—Mediastinal disorder—Latanoprost—glaucoma	0.00243	0.00636	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Bimatoprost—glaucoma	0.00242	0.00636	CcSEcCtD
Linagliptin—Infestation NOS—Apraclonidine—glaucoma	0.0024	0.00629	CcSEcCtD
Linagliptin—Infestation—Apraclonidine—glaucoma	0.0024	0.00629	CcSEcCtD
Linagliptin—Nasopharyngitis—Brimonidine—glaucoma	0.00239	0.00626	CcSEcCtD
Linagliptin—Back pain—Latanoprost—glaucoma	0.00227	0.00595	CcSEcCtD
Linagliptin—Nasopharyngitis—Brinzolamide—glaucoma	0.00224	0.00588	CcSEcCtD
Linagliptin—DPP4—Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)—PAX6—glaucoma	0.00224	0.204	CbGpPWpGaD
Linagliptin—Musculoskeletal discomfort—Metipranolol—glaucoma	0.00215	0.00563	CcSEcCtD
Linagliptin—Infection—Carbachol—glaucoma	0.00208	0.00546	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Dorzolamide—glaucoma	0.00205	0.00537	CcSEcCtD
Linagliptin—Pancreatitis—Pilocarpine—glaucoma	0.00204	0.00536	CcSEcCtD
Linagliptin—Arthralgia—Latanoprost—glaucoma	0.002	0.00523	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Latanoprost—glaucoma	0.00198	0.0052	CcSEcCtD
Linagliptin—Anaphylactic shock—Methazolamide—glaucoma	0.00198	0.00518	CcSEcCtD
Linagliptin—Infestation NOS—Travoprost—glaucoma	0.00196	0.00513	CcSEcCtD
Linagliptin—Infestation—Travoprost—glaucoma	0.00196	0.00513	CcSEcCtD
Linagliptin—Mediastinal disorder—Apraclonidine—glaucoma	0.00194	0.00509	CcSEcCtD
Linagliptin—Infestation NOS—Brinzolamide—glaucoma	0.00193	0.00507	CcSEcCtD
Linagliptin—Infestation—Brinzolamide—glaucoma	0.00193	0.00507	CcSEcCtD
Linagliptin—Diabetes mellitus—Betaxolol—glaucoma	0.00193	0.00505	CcSEcCtD
Linagliptin—Pain in extremity—Clonidine—glaucoma	0.00192	0.00505	CcSEcCtD
Linagliptin—Urinary tract infection—Dorzolamide—glaucoma	0.00191	0.00501	CcSEcCtD
Linagliptin—Urinary tract infection—Travoprost—glaucoma	0.0019	0.00499	CcSEcCtD
Linagliptin—Mediastinal disorder—Bimatoprost—glaucoma	0.00188	0.00493	CcSEcCtD
Linagliptin—Skin disorder—Latanoprost—glaucoma	0.00186	0.00487	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Diclofenamide—glaucoma	0.00185	0.00486	CcSEcCtD
Linagliptin—Constipation—Diclofenamide—glaucoma	0.00184	0.00481	CcSEcCtD
Linagliptin—Urinary tract infection—Pilocarpine—glaucoma	0.00181	0.00474	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Latanoprost—glaucoma	0.00174	0.00457	CcSEcCtD
Linagliptin—Hypersensitivity—Metipranolol—glaucoma	0.00174	0.00455	CcSEcCtD
Linagliptin—Nasopharyngitis—Clonidine—glaucoma	0.00172	0.00451	CcSEcCtD
Linagliptin—Hypoglycaemia—Betaxolol—glaucoma	0.00172	0.0045	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Methazolamide—glaucoma	0.00171	0.00447	CcSEcCtD
Linagliptin—Immune system disorder—Brimonidine—glaucoma	0.00167	0.00438	CcSEcCtD
Linagliptin—Mediastinal disorder—Brimonidine—glaucoma	0.00167	0.00437	CcSEcCtD
Linagliptin—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—PAX6—glaucoma	0.00165	0.151	CbGpPWpGaD
Linagliptin—Urticaria—Levobunolol—glaucoma	0.00164	0.0043	CcSEcCtD
Linagliptin—Hypersensitivity—Carteolol—glaucoma	0.00161	0.00422	CcSEcCtD
Linagliptin—Myalgia—Apraclonidine—glaucoma	0.0016	0.00418	CcSEcCtD
Linagliptin—Immune system disorder—Travoprost—glaucoma	0.00159	0.00416	CcSEcCtD
Linagliptin—Cough—Bimatoprost—glaucoma	0.00159	0.00416	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Apraclonidine—glaucoma	0.00158	0.00416	CcSEcCtD
Linagliptin—Mediastinal disorder—Travoprost—glaucoma	0.00158	0.00415	CcSEcCtD
Linagliptin—Urticaria—Methazolamide—glaucoma	0.00157	0.00412	CcSEcCtD
Linagliptin—Immune system disorder—Brinzolamide—glaucoma	0.00157	0.00411	CcSEcCtD
Linagliptin—Mediastinal disorder—Brinzolamide—glaucoma	0.00156	0.0041	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Clonidine—glaucoma	0.00155	0.00406	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Bimatoprost—glaucoma	0.00154	0.00403	CcSEcCtD
Linagliptin—Hypersensitivity—Levobunolol—glaucoma	0.00152	0.00399	CcSEcCtD
Linagliptin—Infection—Apraclonidine—glaucoma	0.00152	0.00398	CcSEcCtD
Linagliptin—Weight increased—Clonidine—glaucoma	0.00151	0.00397	CcSEcCtD
Linagliptin—Malnutrition—Brinzolamide—glaucoma	0.00151	0.00396	CcSEcCtD
Linagliptin—Nasopharyngitis—Betaxolol—glaucoma	0.0015	0.00393	CcSEcCtD
Linagliptin—Back pain—Dorzolamide—glaucoma	0.00149	0.0039	CcSEcCtD
Linagliptin—Rash—Metipranolol—glaucoma	0.00149	0.0039	CcSEcCtD
Linagliptin—Skin disorder—Apraclonidine—glaucoma	0.00149	0.0039	CcSEcCtD
Linagliptin—Dermatitis—Metipranolol—glaucoma	0.00148	0.00389	CcSEcCtD
Linagliptin—Back pain—Travoprost—glaucoma	0.00148	0.00388	CcSEcCtD
Linagliptin—Headache—Metipranolol—glaucoma	0.00148	0.00387	CcSEcCtD
Linagliptin—Infection—Bimatoprost—glaucoma	0.00147	0.00386	CcSEcCtD
Linagliptin—DPP4—Incretin synthesis, secretion, and inactivation—PAX6—glaucoma	0.00147	0.134	CbGpPWpGaD
Linagliptin—Back pain—Brinzolamide—glaucoma	0.00146	0.00383	CcSEcCtD
Linagliptin—Urinary tract infection—Clonidine—glaucoma	0.00144	0.00378	CcSEcCtD
Linagliptin—Skin disorder—Bimatoprost—glaucoma	0.00144	0.00378	CcSEcCtD
Linagliptin—Diarrhoea—Carbachol—glaucoma	0.00143	0.00376	CcSEcCtD
Linagliptin—Diarrhoea—Levobunolol—glaucoma	0.00141	0.0037	CcSEcCtD
Linagliptin—Back pain—Pilocarpine—glaucoma	0.0014	0.00368	CcSEcCtD
Linagliptin—Angioedema—Dorzolamide—glaucoma	0.0014	0.00368	CcSEcCtD
Linagliptin—Cough—Brimonidine—glaucoma	0.0014	0.00368	CcSEcCtD
Linagliptin—Hypoglycaemia—Timolol—glaucoma	0.0014	0.00368	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Apraclonidine—glaucoma	0.00139	0.00365	CcSEcCtD
Linagliptin—Myalgia—Brimonidine—glaucoma	0.00137	0.00359	CcSEcCtD
Linagliptin—Arthralgia—Brimonidine—glaucoma	0.00137	0.00359	CcSEcCtD
Linagliptin—Pain in extremity—Timolol—glaucoma	0.00137	0.00359	CcSEcCtD
Linagliptin—Anaphylactic shock—Acetazolamide—glaucoma	0.00137	0.00359	CcSEcCtD
Linagliptin—Headache—Carteolol—glaucoma	0.00137	0.00359	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Brimonidine—glaucoma	0.00136	0.00357	CcSEcCtD
Linagliptin—Rash—Diclofenamide—glaucoma	0.00135	0.00355	CcSEcCtD
Linagliptin—Diarrhoea—Methazolamide—glaucoma	0.00135	0.00355	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Betaxolol—glaucoma	0.00135	0.00353	CcSEcCtD
Linagliptin—Headache—Diclofenamide—glaucoma	0.00134	0.00353	CcSEcCtD
Linagliptin—Cough—Dorzolamide—glaucoma	0.00134	0.00352	CcSEcCtD
Linagliptin—Cough—Travoprost—glaucoma	0.00133	0.0035	CcSEcCtD
Linagliptin—Rash—Carbachol—glaucoma	0.00132	0.00346	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Apraclonidine—glaucoma	0.00132	0.00346	CcSEcCtD
Linagliptin—Dermatitis—Carbachol—glaucoma	0.00132	0.00346	CcSEcCtD
Linagliptin—Weight increased—Betaxolol—glaucoma	0.00132	0.00346	CcSEcCtD
Linagliptin—Cough—Brinzolamide—glaucoma	0.00132	0.00346	CcSEcCtD
Linagliptin—Headache—Carbachol—glaucoma	0.00131	0.00344	CcSEcCtD
Linagliptin—Arthralgia—Dorzolamide—glaucoma	0.00131	0.00343	CcSEcCtD
Linagliptin—Constipation—Apraclonidine—glaucoma	0.00131	0.00343	CcSEcCtD
Linagliptin—Infection—Brimonidine—glaucoma	0.0013	0.00342	CcSEcCtD
Linagliptin—Arthralgia—Travoprost—glaucoma	0.0013	0.00342	CcSEcCtD
Linagliptin—Myalgia—Travoprost—glaucoma	0.0013	0.00342	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Travoprost—glaucoma	0.00129	0.00339	CcSEcCtD
Linagliptin—Headache—Levobunolol—glaucoma	0.00129	0.00339	CcSEcCtD
Linagliptin—Infestation NOS—Betaxolol—glaucoma	0.00129	0.00339	CcSEcCtD
Linagliptin—Infestation—Betaxolol—glaucoma	0.00129	0.00339	CcSEcCtD
Linagliptin—Myalgia—Brinzolamide—glaucoma	0.00129	0.00337	CcSEcCtD
Linagliptin—Arthralgia—Brinzolamide—glaucoma	0.00129	0.00337	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Bimatoprost—glaucoma	0.00128	0.00336	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Brinzolamide—glaucoma	0.00128	0.00335	CcSEcCtD
Linagliptin—Skin disorder—Brimonidine—glaucoma	0.00128	0.00334	CcSEcCtD
Linagliptin—Cough—Pilocarpine—glaucoma	0.00127	0.00332	CcSEcCtD
Linagliptin—Anaphylactic shock—Dorzolamide—glaucoma	0.00125	0.00329	CcSEcCtD
Linagliptin—Rash—Methazolamide—glaucoma	0.00125	0.00327	CcSEcCtD
Linagliptin—Dermatitis—Methazolamide—glaucoma	0.00124	0.00326	CcSEcCtD
Linagliptin—Infection—Travoprost—glaucoma	0.00124	0.00325	CcSEcCtD
Linagliptin—Headache—Methazolamide—glaucoma	0.00124	0.00325	CcSEcCtD
Linagliptin—Arthralgia—Pilocarpine—glaucoma	0.00124	0.00324	CcSEcCtD
Linagliptin—Myalgia—Pilocarpine—glaucoma	0.00124	0.00324	CcSEcCtD
Linagliptin—Infection—Brinzolamide—glaucoma	0.00122	0.00321	CcSEcCtD
Linagliptin—Nasopharyngitis—Timolol—glaucoma	0.00122	0.00321	CcSEcCtD
Linagliptin—Skin disorder—Travoprost—glaucoma	0.00121	0.00318	CcSEcCtD
Linagliptin—Rash—Latanoprost—glaucoma	0.00121	0.00316	CcSEcCtD
Linagliptin—Dermatitis—Latanoprost—glaucoma	0.0012	0.00316	CcSEcCtD
Linagliptin—Mediastinal disorder—Clonidine—glaucoma	0.0012	0.00315	CcSEcCtD
Linagliptin—Headache—Latanoprost—glaucoma	0.0012	0.00314	CcSEcCtD
Linagliptin—Skin disorder—Brinzolamide—glaucoma	0.0012	0.00314	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Brimonidine—glaucoma	0.0012	0.00314	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Acetazolamide—glaucoma	0.00118	0.0031	CcSEcCtD
Linagliptin—Infection—Pilocarpine—glaucoma	0.00118	0.00309	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Dorzolamide—glaucoma	0.00114	0.003	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Travoprost—glaucoma	0.00114	0.00298	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Brimonidine—glaucoma	0.00113	0.00297	CcSEcCtD
Linagliptin—Hypersensitivity—Apraclonidine—glaucoma	0.00113	0.00296	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Brinzolamide—glaucoma	0.00112	0.00295	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Timolol—glaucoma	0.0011	0.00288	CcSEcCtD
Linagliptin—Urticaria—Acetazolamide—glaucoma	0.00109	0.00285	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Pilocarpine—glaucoma	0.00108	0.00283	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Travoprost—glaucoma	0.00108	0.00283	CcSEcCtD
Linagliptin—Constipation—Travoprost—glaucoma	0.00107	0.0028	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Brinzolamide—glaucoma	0.00106	0.00279	CcSEcCtD
Linagliptin—Angioedema—Clonidine—glaucoma	0.00106	0.00278	CcSEcCtD
Linagliptin—Immune system disorder—Betaxolol—glaucoma	0.00105	0.00275	CcSEcCtD
Linagliptin—Diarrhoea—Apraclonidine—glaucoma	0.00105	0.00274	CcSEcCtD
Linagliptin—Mediastinal disorder—Betaxolol—glaucoma	0.00104	0.00274	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Pilocarpine—glaucoma	0.00102	0.00268	CcSEcCtD
Linagliptin—Constipation—Pilocarpine—glaucoma	0.00101	0.00266	CcSEcCtD
Linagliptin—Cough—Clonidine—glaucoma	0.00101	0.00265	CcSEcCtD
Linagliptin—Malnutrition—Betaxolol—glaucoma	0.00101	0.00265	CcSEcCtD
Linagliptin—Urticaria—Dorzolamide—glaucoma	0.000996	0.00261	CcSEcCtD
Linagliptin—Arthralgia—Clonidine—glaucoma	0.000987	0.00259	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.00098	0.00257	CcSEcCtD
Linagliptin—Urticaria—Brinzolamide—glaucoma	0.000979	0.00257	CcSEcCtD
Linagliptin—Hypersensitivity—Brimonidine—glaucoma	0.000967	0.00254	CcSEcCtD
Linagliptin—Dermatitis—Apraclonidine—glaucoma	0.000963	0.00253	CcSEcCtD
Linagliptin—Headache—Apraclonidine—glaucoma	0.000958	0.00251	CcSEcCtD
Linagliptin—Infection—Clonidine—glaucoma	0.00094	0.00247	CcSEcCtD
Linagliptin—Diarrhoea—Acetazolamide—glaucoma	0.000936	0.00245	CcSEcCtD
Linagliptin—Rash—Bimatoprost—glaucoma	0.000935	0.00245	CcSEcCtD
Linagliptin—DPP4—Peptide hormone metabolism—ACE2—glaucoma	0.000935	0.0853	CbGpPWpGaD
Linagliptin—Dermatitis—Bimatoprost—glaucoma	0.000934	0.00245	CcSEcCtD
Linagliptin—Headache—Bimatoprost—glaucoma	0.000929	0.00244	CcSEcCtD
Linagliptin—Hypersensitivity—Dorzolamide—glaucoma	0.000924	0.00242	CcSEcCtD
Linagliptin—Hypersensitivity—Travoprost—glaucoma	0.00092	0.00241	CcSEcCtD
Linagliptin—Skin disorder—Clonidine—glaucoma	0.000919	0.00241	CcSEcCtD
Linagliptin—Hypersensitivity—Brinzolamide—glaucoma	0.000908	0.00238	CcSEcCtD
Linagliptin—Cough—Betaxolol—glaucoma	0.000881	0.00231	CcSEcCtD
Linagliptin—Hypersensitivity—Pilocarpine—glaucoma	0.000873	0.00229	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Clonidine—glaucoma	0.000862	0.00226	CcSEcCtD
Linagliptin—Myalgia—Betaxolol—glaucoma	0.000859	0.00225	CcSEcCtD
Linagliptin—Arthralgia—Betaxolol—glaucoma	0.000859	0.00225	CcSEcCtD
Linagliptin—Diarrhoea—Dorzolamide—glaucoma	0.000858	0.00225	CcSEcCtD
Linagliptin—Headache—Acetazolamide—glaucoma	0.000857	0.00225	CcSEcCtD
Linagliptin—Immune system disorder—Timolol—glaucoma	0.000855	0.00224	CcSEcCtD
Linagliptin—Diarrhoea—Travoprost—glaucoma	0.000854	0.00224	CcSEcCtD
Linagliptin—Mediastinal disorder—Timolol—glaucoma	0.000853	0.00224	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000853	0.00224	CcSEcCtD
Linagliptin—Diarrhoea—Brinzolamide—glaucoma	0.000843	0.00221	CcSEcCtD
Linagliptin—Rash—Brimonidine—glaucoma	0.000828	0.00217	CcSEcCtD
Linagliptin—Dermatitis—Brimonidine—glaucoma	0.000827	0.00217	CcSEcCtD
Linagliptin—Malnutrition—Timolol—glaucoma	0.000824	0.00216	CcSEcCtD
Linagliptin—Headache—Brimonidine—glaucoma	0.000822	0.00216	CcSEcCtD
Linagliptin—Infection—Betaxolol—glaucoma	0.000818	0.00215	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Clonidine—glaucoma	0.000817	0.00214	CcSEcCtD
Linagliptin—Diarrhoea—Pilocarpine—glaucoma	0.000811	0.00213	CcSEcCtD
Linagliptin—Constipation—Clonidine—glaucoma	0.000809	0.00212	CcSEcCtD
Linagliptin—Skin disorder—Betaxolol—glaucoma	0.0008	0.0021	CcSEcCtD
Linagliptin—Rash—Dorzolamide—glaucoma	0.00079	0.00207	CcSEcCtD
Linagliptin—Dermatitis—Dorzolamide—glaucoma	0.00079	0.00207	CcSEcCtD
Linagliptin—Rash—Travoprost—glaucoma	0.000787	0.00206	CcSEcCtD
Linagliptin—Dermatitis—Travoprost—glaucoma	0.000786	0.00206	CcSEcCtD
Linagliptin—Headache—Dorzolamide—glaucoma	0.000785	0.00206	CcSEcCtD
Linagliptin—Headache—Travoprost—glaucoma	0.000782	0.00205	CcSEcCtD
Linagliptin—Rash—Brinzolamide—glaucoma	0.000777	0.00204	CcSEcCtD
Linagliptin—Dermatitis—Brinzolamide—glaucoma	0.000776	0.00204	CcSEcCtD
Linagliptin—Headache—Brinzolamide—glaucoma	0.000772	0.00203	CcSEcCtD
Linagliptin—Angioedema—Timolol—glaucoma	0.000753	0.00198	CcSEcCtD
Linagliptin—Urticaria—Clonidine—glaucoma	0.000752	0.00197	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Betaxolol—glaucoma	0.00075	0.00197	CcSEcCtD
Linagliptin—Rash—Pilocarpine—glaucoma	0.000747	0.00196	CcSEcCtD
Linagliptin—Dermatitis—Pilocarpine—glaucoma	0.000746	0.00196	CcSEcCtD
Linagliptin—Headache—Pilocarpine—glaucoma	0.000742	0.00195	CcSEcCtD
Linagliptin—Cough—Timolol—glaucoma	0.000719	0.00189	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Betaxolol—glaucoma	0.000711	0.00187	CcSEcCtD
Linagliptin—Constipation—Betaxolol—glaucoma	0.000704	0.00185	CcSEcCtD
Linagliptin—Myalgia—Timolol—glaucoma	0.000702	0.00184	CcSEcCtD
Linagliptin—Arthralgia—Timolol—glaucoma	0.000702	0.00184	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000697	0.00183	CcSEcCtD
Linagliptin—Hypersensitivity—Clonidine—glaucoma	0.000697	0.00183	CcSEcCtD
Linagliptin—Anaphylactic shock—Timolol—glaucoma	0.000673	0.00176	CcSEcCtD
Linagliptin—Infection—Timolol—glaucoma	0.000668	0.00175	CcSEcCtD
Linagliptin—Urticaria—Betaxolol—glaucoma	0.000654	0.00172	CcSEcCtD
Linagliptin—Skin disorder—Timolol—glaucoma	0.000654	0.00171	CcSEcCtD
Linagliptin—Diarrhoea—Clonidine—glaucoma	0.000647	0.0017	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Timolol—glaucoma	0.000613	0.00161	CcSEcCtD
Linagliptin—Hypersensitivity—Betaxolol—glaucoma	0.000607	0.00159	CcSEcCtD
Linagliptin—ABCB1—ABC-family proteins mediated transport—PEX19—glaucoma	0.000604	0.0551	CbGpPWpGaD
Linagliptin—Rash—Clonidine—glaucoma	0.000596	0.00156	CcSEcCtD
Linagliptin—Dermatitis—Clonidine—glaucoma	0.000596	0.00156	CcSEcCtD
Linagliptin—Headache—Clonidine—glaucoma	0.000593	0.00155	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Timolol—glaucoma	0.000581	0.00152	CcSEcCtD
Linagliptin—Diarrhoea—Betaxolol—glaucoma	0.000564	0.00148	CcSEcCtD
Linagliptin—Urticaria—Timolol—glaucoma	0.000535	0.0014	CcSEcCtD
Linagliptin—Rash—Betaxolol—glaucoma	0.000519	0.00136	CcSEcCtD
Linagliptin—Dermatitis—Betaxolol—glaucoma	0.000519	0.00136	CcSEcCtD
Linagliptin—Headache—Betaxolol—glaucoma	0.000516	0.00135	CcSEcCtD
Linagliptin—DPP4—Peptide hormone metabolism—PAX6—glaucoma	0.000499	0.0455	CbGpPWpGaD
Linagliptin—Hypersensitivity—Timolol—glaucoma	0.000496	0.0013	CcSEcCtD
Linagliptin—Diarrhoea—Timolol—glaucoma	0.00046	0.00121	CcSEcCtD
Linagliptin—Rash—Timolol—glaucoma	0.000424	0.00111	CcSEcCtD
Linagliptin—Dermatitis—Timolol—glaucoma	0.000424	0.00111	CcSEcCtD
Linagliptin—Headache—Timolol—glaucoma	0.000421	0.00111	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—DHPS—glaucoma	0.000307	0.028	CbGpPWpGaD
Linagliptin—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—glaucoma	0.000258	0.0235	CbGpPWpGaD
Linagliptin—CYP3A4—Aflatoxin B1 metabolism—GSTM1—glaucoma	0.000252	0.023	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—CTSA—glaucoma	0.000192	0.0175	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—ACE2—glaucoma	0.000176	0.0161	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PITX2—glaucoma	0.000159	0.0145	CbGpPWpGaD
Linagliptin—CYP3A4—Estrogen metabolism—CYP1B1—glaucoma	0.000148	0.0135	CbGpPWpGaD
Linagliptin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000145	0.0132	CbGpPWpGaD
Linagliptin—CYP3A4—Tamoxifen metabolism—CYP1B1—glaucoma	0.000131	0.012	CbGpPWpGaD
Linagliptin—CYP3A4—Estrogen metabolism—GSTM1—glaucoma	0.000119	0.0108	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—PAX6—glaucoma	9.41e-05	0.00859	CbGpPWpGaD
Linagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	8.91e-05	0.00813	CbGpPWpGaD
Linagliptin—CYP3A4—Tryptophan metabolism—CYP1B1—glaucoma	7e-05	0.00638	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—EDN1—glaucoma	6.88e-05	0.00628	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—PEX19—glaucoma	6.32e-05	0.00576	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IL1A—glaucoma	5.93e-05	0.00541	CbGpPWpGaD
Linagliptin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	5.66e-05	0.00516	CbGpPWpGaD
Linagliptin—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—glaucoma	5.58e-05	0.00509	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—MMP1—glaucoma	5.36e-05	0.00489	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—FAS—glaucoma	5.28e-05	0.00482	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—C3—glaucoma	5.21e-05	0.00475	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—glaucoma	4.61e-05	0.00421	CbGpPWpGaD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	4.59e-05	0.00418	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	4.46e-05	0.00407	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC4A4—glaucoma	4.27e-05	0.00389	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—MMP2—glaucoma	4.15e-05	0.00378	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CA5A—glaucoma	3.48e-05	0.00317	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NARFL—glaucoma	3.48e-05	0.00317	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	3.33e-05	0.00303	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	3.07e-05	0.0028	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTT1—glaucoma	3.06e-05	0.00279	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	3.05e-05	0.00278	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—glaucoma	3.02e-05	0.00276	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC6A13—glaucoma	2.85e-05	0.0026	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—VEGFA—glaucoma	2.62e-05	0.00239	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	2.61e-05	0.00238	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—CYP1B1—glaucoma	2.44e-05	0.00222	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—CYP1B1—glaucoma	2.4e-05	0.00219	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—TNF—glaucoma	2.24e-05	0.00205	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	2.23e-05	0.00203	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CA5A—glaucoma	2.14e-05	0.00196	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NARFL—glaucoma	2.14e-05	0.00196	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC6A1—glaucoma	2.08e-05	0.0019	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTM1—glaucoma	1.95e-05	0.00178	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTM1—glaucoma	1.92e-05	0.00175	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CA1—glaucoma	1.7e-05	0.00155	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CTSA—glaucoma	1.65e-05	0.0015	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	1.64e-05	0.0015	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CA2—glaucoma	1.55e-05	0.00142	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	1.55e-05	0.00142	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	1.29e-05	0.00118	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	1.11e-05	0.00101	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—TXN—glaucoma	1.09e-05	0.000999	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CA1—glaucoma	1.05e-05	0.000955	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CTSA—glaucoma	1.01e-05	0.000925	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	9.76e-06	0.00089	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CA2—glaucoma	9.57e-06	0.000873	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTT1—glaucoma	8.49e-06	0.000774	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ABCA1—glaucoma	6.76e-06	0.000617	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP1B1—glaucoma	6.76e-06	0.000617	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—TXN—glaucoma	6.75e-06	0.000615	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTM1—glaucoma	5.41e-06	0.000493	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTT1—glaucoma	5.23e-06	0.000477	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—MTHFR—glaucoma	4.78e-06	0.000436	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—APOE—glaucoma	4.45e-06	0.000406	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CAV1—glaucoma	4.41e-06	0.000402	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP1B1—glaucoma	4.17e-06	0.00038	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ABCA1—glaucoma	4.17e-06	0.00038	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NOS3—glaucoma	3.33e-06	0.000304	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTM1—glaucoma	3.33e-06	0.000304	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PTGS2—glaucoma	3.05e-06	0.000278	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—MTHFR—glaucoma	2.94e-06	0.000269	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—APOE—glaucoma	2.74e-06	0.00025	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CAV1—glaucoma	2.72e-06	0.000248	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NOS3—glaucoma	2.05e-06	0.000187	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PTGS2—glaucoma	1.88e-06	0.000171	CbGpPWpGaD
